Gimsilumab (MORAb-022)

Current Studies

Gimsilumab Phase 1 Study (Completed)

This clinical study was a Phase 1, randomized, double-blind, placebo-controlled, single-dose, dose-escalation trial of gimsilumab in healthy patients and patients with rheumatoid arthritis.

This trial to evaluate the safety and tolerability of single escalating intravenous (IV) doses of gimsilumab in healthy patients and patients with rheumatoid arthritis (RA) has been completed. The top-line data were reported in a December 7, 2015 press release.

For more information visit ClinicalTrials.gov. (Identifier: NCT01357759)

For more information about gimsilumab, please click here


The information contained herein is investigational and is not intended to make claims of safety or efficacy prior to approval by the FDA or other regulatory authorities. There is no guarantee that the agents described or their uses will be approved by the FDA or other regulatory authorities.